Showing results (21-30 of 518) with videos related to
Sort By:
Pageof 52
Future Oncology (London, England)|October 10, 2015
AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patientsJordi Remon, David PlanchardESMO Open|November 15, 2018
Precision oncology: separating the wheat from the chaffJordi Remon, Rodrigo DienstmannTumori|May 21, 2016
Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancerFrancesco Facchinetti, Caroline Caramella, Nathalie Auger, et al.Clinical Lung Cancer|March 26, 2017
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613Jordi Remon, Jessica Menis, Baktiar Hasan, et al.Translational Lung Cancer Research|July 23, 2021
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancerBoris Duchemann, Jordi Remon, Marie Naigeon, et al.Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic valueFrancesco Facchinetti, Maria Virginia Bluthgen, Gabrielle Tergemina-Clain, et al.Bulletin Du Cancer|June 30, 2015
[Is chemotherapy still a valid option for oncogene-addicted lung cancer? Yes]Benjamin BesseCurrent Opinion in Oncology|January 13, 2016
Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancerJordi Remon, Nathalie Chaput, David PlanchardCancer Management and Research|June 20, 2019
Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to dateJordi Remon, Laura Esteller, Álvaro TausCancer Treatment Reviews|July 20, 2011
Brain metastases from renal cell carcinoma. Should we change the current standard?Jordi Remon, Pilar Lianes, Susana MartínezPageof 52